Details of the Drug

General Information of Drug (ID: DMBIGTU)

Drug Name

SB-728-mR-T

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus-1 infection	1C62	Phase 1/2	[1]
------------------------------------------------------------------------------------

Drug Type

Cell therapy

Cross-matching ID

References

1	ClinicalTrials.gov (NCT02225665) A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning. U.S.National Institutes of Health.